Portfoliotracker

ARS Pharmaceuticals, Inc.

SPRY · NASDAQGM · Healthcare Biotechnology 19/100 E

3,590 $
▼ −0,300 (−7,71 %)
Pre-market delayed by 15 min
Price as of 16. 11. 22:00, fetched 17. 11. 13:24
Next earnings–
Ex-dividend–
Analysts–
50 / 200 day average– / –

Price

Portfoliotracker score19 / 100 Market cap358 mil. $ P/E– Forward P/E-4,3 P/S2,9 P/B– EV/EBITDA– Dividend yield– FCF yield-51,16 % EPS-2,01 $ Net margin-163,6 % Return on equity-294,6 % Beta1,16 Debt / equity–
52-week range 2,44 to 13,15
3-month average volume1,8 M

Finance

Where the revenue goes

Loading the income statement flow…

Fundamentals

Loading key figures…

Insiders, analysts and people

All trades and changes

Loading insiders, analysts and opinions…

Co se právě děje

AI souhrn
Objednat AI souhrn, co se u firmy právě děje Vytvoří se jednou na pozadí a pak ho uvidí všichni. Ve verzi Free 3 objednávky měsíčně.

About the company

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

Employees
203
Country
United States
Fiscal year end
31. 12.
Data since
4. 12. 2020

Explore further

Similar companies EWTXPHATTVTXTARSTNGX

Intraday chart

Your own portfolio, properties and finances in one place.

The account is free with no time limit. Only you see your data; nobody adds it up with others.

This is saved to your account. You can keep browsing, calculating and comparing without signing in.

Welcome back

Sign in and pick up where you left off.

or continue with

No account yet? Create a free account